Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

No evidence for globally coherent warm and cold periods over the preindustrial Common Era.

Neukom R, Steiger N, Gómez-Navarro JJ, Wang J, Werner JP.

Nature. 2019 Jul;571(7766):550-554. doi: 10.1038/s41586-019-1401-2. Epub 2019 Jul 24.

PMID:
31341300
2.

Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON -1 Study.

Suri A, Mould DR, Song G, Collins GP, Endres CJ, Gomez-Navarro J, Venkatakrishnan K.

Clin Pharmacol Ther. 2019 Jun 1. doi: 10.1002/cpt.1530. [Epub ahead of print]

PMID:
31152605
3.

Perspectives of regional paleoclimate modeling.

Ludwig P, Gómez-Navarro JJ, Pinto JG, Raible CC, Wagner S, Zorita E.

Ann N Y Acad Sci. 2019 Jan;1436(1):54-69. doi: 10.1111/nyas.13865. Epub 2018 Jun 4. Review.

PMID:
29863800
4.

From global circulation to local flood loss: Coupling models across the scales.

Felder G, Gómez-Navarro JJ, Zischg AP, Raible CC, Röthlisberger V, Bozhinova D, Martius O, Weingartner R.

Sci Total Environ. 2018 Sep 1;635:1225-1239. doi: 10.1016/j.scitotenv.2018.04.170. Epub 2018 Apr 24.

PMID:
29710577
5.

[Archibald Cochrane: evidence, effectiveness and decision-making in health].

Hortiales González AF, Gómez Navarro JA, Barajas Nava LA, Garduño Espinosa J.

Bol Med Hosp Infant Mex. 2017 Sep - Oct;74(5):319-323. doi: 10.1016/j.bmhimx.2017.02.007. Epub 2017 Aug 25. Review. Spanish.

6.

Surgical Site Infection Rate Drops to 0% Using a Vacuum-Assisted Closure in Contaminated/Dirty Infected Laparotomy Wounds.

Lozano-Balderas G, Ruiz-Velasco-Santacruz A, Díaz-Elizondo JA, Gómez-Navarro JA, Flores-Villalba E.

Am Surg. 2017 May 1;83(5):512-514.

PMID:
28541864
7.

Bromine soil/sediment enrichment in tidal salt marshes as a potential indicator of climate changes driven by solar activity: New insights from W coast Portuguese estuaries.

Moreno J, Fatela F, Leorri E, Moreno F, Freitas MC, Valente T, Araújo MF, Gómez-Navarro JJ, Guise L, Blake WH.

Sci Total Environ. 2017 Feb 15;580:324-338. doi: 10.1016/j.scitotenv.2016.11.130. Epub 2016 Dec 27.

PMID:
28034544
8.

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.

Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R.

Oncotarget. 2015 Jun 10;6(16):14139-52.

9.

Natural killer T cells in advanced melanoma patients treated with tremelimumab.

Ibarrondo FJ, Yang OO, Chodon T, Avramis E, Lee Y, Sazegar H, Jalil J, Chmielowski B, Koya RC, Schmid I, Gomez-Navarro J, Jamieson BD, Ribas A, Comin-Anduix B.

PLoS One. 2013 Oct 22;8(10):e76829. doi: 10.1371/journal.pone.0076829. eCollection 2013.

10.

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.

Millward M, Underhill C, Lobb S, McBurnie J, Meech SJ, Gomez-Navarro J, Marshall MA, Huang B, Mather CB.

Br J Cancer. 2013 May 28;108(10):1998-2004. doi: 10.1038/bjc.2013.227. Epub 2013 May 7.

11.

Screening for polyphenols, antioxidant and antimicrobial activitiesof extracts from eleven Helianthemum taxa (Cistaceae) used in folk medicine in south-eastern Spain.

Rubio-Moraga A, Argandoña J, Mota B, Pérez J, Verde A, Fajardo J, Gómez-Navarro J, Castillo-López R, Ahrazem O, Gómez-Gómez L.

J Ethnopharmacol. 2013 Jun 21;148(1):287-96. doi: 10.1016/j.jep.2013.04.028. Epub 2013 Apr 21.

PMID:
23615124
12.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A.

J Clin Oncol. 2013 Feb 10;31(5):616-22. doi: 10.1200/JCO.2012.44.6112. Epub 2013 Jan 7.

13.

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.

Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R.

J Transl Med. 2012 Nov 21;10:236. doi: 10.1186/1479-5876-10-236.

14.

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.

Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A.

Clin Cancer Res. 2011 Jun 15;17(12):4101-9. doi: 10.1158/1078-0432.CCR-11-0407. Epub 2011 May 10.

15.

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma.

Comin-Anduix B, Sazegar H, Chodon T, Matsunaga D, Jalil J, von Euw E, Escuin-Ordinas H, Balderas R, Chmielowski B, Gomez-Navarro J, Koya RC, Ribas A.

PLoS One. 2010 Sep 15;5(9):e12711. doi: 10.1371/journal.pone.0012711.

16.

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.

Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB.

J Clin Oncol. 2010 Jul 20;28(21):3485-90. doi: 10.1200/JCO.2010.28.3994. Epub 2010 May 24.

PMID:
20498386
17.

Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab.

Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J.

J Nucl Med. 2010 Mar;51(3):340-6. doi: 10.2967/jnumed.109.070946. Epub 2010 Feb 11.

18.

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.

Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, Marshall MA, Gomez-Navarro J, Liang JQ, Bulanhagui CA.

Clin Cancer Res. 2010 Feb 1;16(3):1042-8. doi: 10.1158/1078-0432.CCR-09-2033. Epub 2010 Jan 19.

19.

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.

Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J.

Clin Cancer Res. 2009 Oct 1;15(19):6267-76. doi: 10.1158/1078-0432.CCR-09-1254. Epub 2009 Sep 29.

20.

Phase I/II trial of tremelimumab in patients with metastatic melanoma.

Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A.

J Clin Oncol. 2009 Mar 1;27(7):1075-81. doi: 10.1200/JCO.2008.19.2435. Epub 2009 Jan 12.

PMID:
19139427
21.

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.

Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ.

Clin Cancer Res. 2009 Jan 1;15(1):390-9. doi: 10.1158/1078-0432.CCR-08-0783.

22.

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.

Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A.

J Transl Med. 2008 May 1;6:22. doi: 10.1186/1479-5876-6-22.

23.

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.

Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, Bernstein SH, Canniff PC, Sharma A, Gomez-Navarro J.

Oncologist. 2007 Jul;12(7):873-83. Review.

24.

Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.

Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, Gomez-Navarro J, Ribas A.

Am J Ophthalmol. 2007 Jun;143(6):958-969. Epub 2007 Apr 16.

PMID:
17434437
25.

Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.

Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH.

Cancer. 2006 Jun 1;106(11):2437-44.

26.

Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays.

Comin-Anduix B, Gualberto A, Glaspy JA, Seja E, Ontiveros M, Reardon DL, Renteria R, Englahner B, Economou JS, Gomez-Navarro J, Ribas A.

Clin Cancer Res. 2006 Jan 1;12(1):107-16.

27.

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J.

J Clin Oncol. 2005 Dec 10;23(35):8968-77. Epub 2005 Oct 3.

PMID:
16204013
28.

An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma.

Arafat WO, Buchsbaum DJ, Gómez-Navarro J, Tawil SA, Olsen C, Xiang J, El-Akad H, Salama AM, Badib AO, Stackhouse MA, Curiel DT.

Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):1037-50.

PMID:
12605984
29.

Conditionally replicative adenoviral vectors for cancer gene therapy.

Gómez-Navarro J, Curiel DT.

Lancet Oncol. 2000 Nov;1:148-58. Review.

PMID:
11905653
30.

Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv.

Arafat WO, Gómez-Navarro J, Buchsbaum DJ, Xiang J, Wang M, Casado E, Barker SD, Mahasreshti PJ, Haisma HJ, Barnes MN, Siegal GP, Alvarez RD, Hemminki A, Nettelbeck DM, Curiel DT.

Gene Ther. 2002 Feb;9(4):256-62.

31.

Bax-induced apoptosis as a novel gene therapy approach for carcinoma of the cervix.

Huh WK, Gomez-Navarro J, Arafat WO, Xiang J, Mahasreshti PJ, Alvarez RD, Barnes MN, Curiel DT.

Gynecol Oncol. 2001 Nov;83(2):370-7.

PMID:
11606099
32.

An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression.

Hemminki A, Belousova N, Zinn KR, Liu B, Wang M, Chaudhuri TR, Rogers BE, Buchsbaum DJ, Siegal GP, Barnes MN, Gomez-Navarro J, Curiel DT, Alvarez RD.

Mol Ther. 2001 Sep;4(3):223-31.

33.

Transcriptional targeting for ovarian cancer gene therapy.

Casado E, Nettelbeck DM, Gomez-Navarro J, Hemminki A, Gonzalez Baron M, Siegal GP, Barnes MN, Alvarez RD, Curiel DT.

Gynecol Oncol. 2001 Aug;82(2):229-37. Review.

PMID:
11531272
34.

Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications.

Casado E, Gomez-Navarro J, Yamamoto M, Adachi Y, Coolidge CJ, Arafat WO, Barker SD, Wang MH, Mahasreshti PJ, Hemminki A, Gonzalez-Baron M, Barnes MN, Pustilnik TB, Siegal GP, Alvarez RD, Curiel DT.

Clin Cancer Res. 2001 Aug;7(8):2496-504.

35.

An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites.

Barker SD, Casado E, Gomez-Navarro J, Xiang J, Arafat W, Mahasreshti P, Pustilnik TB, Hemminki A, Siegal GP, Alvarez RD, Curiel DT.

Gynecol Oncol. 2001 Jul;82(1):57-63.

PMID:
11426962
36.

Gene therapy for carcinoma of the breast: Pro-apoptotic gene therapy.

Gómez-Navarro J, Arafat W, Xiang J.

Breast Cancer Res. 2000;2(1):32-44. Epub 1999 Dec 17. Review.

37.

Selective transduction of murine myelomonocytic leukemia cells (WEHI-3B) with regular and RGD-adenoviral vectors.

García-Castro J, Segovia JC, García-Sánchez F, Lillo R, Gómez-Navarro J, Curiel DT, Bueren JA.

Mol Ther. 2001 Jan;3(1):70-7.

38.

Genetically modified CD34+ cells exert a cytotoxic bystander effect on human endothelial and cancer cells.

Arafat WO, Casado E, Wang M, Alvarez RD, Siegal GP, Glorioso JC, Curiel DT, Gómez-Navarro J.

Clin Cancer Res. 2000 Nov;6(11):4442-8.

39.

Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro.

Kelly FJ, Miller CR, Buchsbaum DJ, Gomez-Navarro J, Barnes MN, Alvarez RD, Curiel DT.

Clin Cancer Res. 2000 Nov;6(11):4323-33.

40.

Adenoviral-mediated suicide gene therapy for ovarian cancer.

Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB, Arafat W, Hughes JV, Siegal GP, Curiel DT.

Mol Ther. 2000 Nov;2(5):524-30.

41.

Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target.

Arafat W, Gómez-Navarro J, Xiang J, Siegal GP, Alvarez RD, Curiel DT.

Cancer Gene Ther. 2000 Sep;7(9):1250-6.

42.

A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.

Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat W, Arani RB, Johnson MR, Roberts BL, Siegal GP, Curiel DT.

Clin Cancer Res. 2000 Aug;6(8):3081-7.

43.

Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid.

Blackwell JL, Li H, Gomez-Navarro J, Dmitriev I, Krasnykh V, Richter CA, Shaw DR, Alvarez RD, Curiel DT, Strong TV.

Hum Gene Ther. 2000 Aug 10;11(12):1657-69.

PMID:
10954900
44.

An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer.

Arafat WO, Gómez-Navarro J, Xiang J, Barnes MN, Mahasreshti P, Alvarez RD, Siegal GP, Badib AO, Buchsbaum D, Curiel DT, Stackhouse MA.

Mol Ther. 2000 Jun;1(6):545-54.

45.

Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer.

Xiang J, Gómez-Navarro J, Arafat W, Liu B, Barker SD, Alvarez RD, Siegal GP, Curiel DT.

J Gene Med. 2000 Mar-Apr;2(2):97-106.

PMID:
10809143
46.

Gene therapy for cancer.

Gómez-Navarro J, Curiel DT, Douglas JT.

Eur J Cancer. 1999 Dec;35(14):2039-57. Review. No abstract available.

PMID:
10711245
47.

Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model.

Gómez-Navarro J, Contreras JL, Arafat W, Jiang XL, Krisky D, Oligino T, Marconi P, Hubbard B, Glorioso JC, Curiel DT, Thomas JM.

Gene Ther. 2000 Jan;7(1):43-52.

48.

9 intracellular single-chain antibodies for gene therapy.

Bilbao G, Gomez-Navarro J, Kazano K, Luis Contreras J, Curiel DT.

Methods Mol Med. 2000;35:121-49. doi: 10.1385/1-59259-086-1:121.

PMID:
21390804
49.

Gene therapy for cancer.

Gómez-Navarro J, Curiel DT, Douglas JT.

Eur J Cancer. 1999 Jun;35(6):867-85. Review. No abstract available.

PMID:
10533466
50.

An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches.

Vanderkwaak TJ, Wang M, Gómez-Navarro J, Rancourt C, Dmitriev I, Krasnykh V, Barnes M, Siegal GP, Alvarez R, Curiel DT.

Gynecol Oncol. 1999 Aug;74(2):227-34.

PMID:
10419736

Supplemental Content

Loading ...
Support Center